News & Events
Insight TNBCtype™, the first and only CLIA-validated assay for triple negative breast cancer (TNBC) molecular subtyping, was featured in two posters on December 7 at the 2018 San Antonio Breast Cancer Symposium (SABCS).
Insight Genetics Presented Presents Posters on Immune Cell Involvement in TNBC at San Antonio Breast Cancer Symposium
Insight Genetics, Inc.’s proprietary Insight TNBCtype™ algorithm was featured in two posters on triple negative breast cancer (TNBC) presented on December 7 at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Insight Genetics will attend the Association for Molecular Pathology (AMP) 2015 Annual Meeting in Austin, Texas from November 4-7, 2015. At the event, Insight Genetics will be available to discuss its current programs focused on enabling precision medicine in non-small cell lung cancer and triple-negative breast cancer as well as its service offerings including custom assay design and development and specialized pharmaceutical services.
Insight Genetics Presents Poster at the 16th World Conference on Lung Cancer and Attends the World CDx Boston Summit
Insight Genetics presented a poster on September 7 at the International Association for the Study of Lung Cancer’s 16th Annual World Conference on Lung Cancer in Denver and will attend the 6th Annual World CDx Boston Summit from September 8-10.
Dr. Rachel Skelton, Insight Genetics’ Regulatory Scientist I, presented at the 4th Annual Clinical Operations in Oncology Trials East Coast 2015 conference on July 15, 2015 in Boston, Massachusetts.